Clinical trials: Choroid Diseases
Intraocular Melanoma
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00952939
- Testing
- fluorescence in situ hybridization, laboratory biomarker analysis, fine-needle aspiration
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: SU5416 may stop the growth of brain cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the safety of delivering SU5416 in children who have recurrent or progressive brain tumors.
- Trial name
- NCT00006247
- Testing
- semaxanib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pediatric Brain Tumor Consortium
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor.
- Trial name
- NCT00005815
- Testing
- temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Age-related Macular Degeneration
Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion
The purpose of the present study was to evaluate the proportion of eyes that do not meet the eligibility criteria of clinical trials on neovascular AMD among the entire sample of eyes diagnosed with treatment-naïve neovascular…
- Trial name
- NCT04836143
- Testing
- Intravitreal anti-vascular endothelial growth factor injection
- Where
- South Korea
- Volunteers
- 512 people
- Sponsor
- Kim's Eye Hospital
Exudative Age-related Macular Degeneration
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation…
- Trial name
- NCT01810042
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Pusan National University Hospital
Central Retinal Vein Occlusion, Choroidal Neovascularization
A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye
This is a research study to evaluate the effects of repeated intravitreal injections on bacteria around the eye.
- Conditions
- Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
- Trial name
- NCT01531842
- Testing
- Conj flora Antibiotic resistance
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mid Atlantic Retina
Polypoidal Choroidal Vasculopathy
OCTA and Polypoidal Choroidal Vasculopathy
To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.
- Trial name
- NCT04714242
- Testing
- Ranibizumab Injection
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Federico II University
Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Choroidal Neovascularization
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.
- Trial name
- NCT04782271
- Testing
- SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.
Brain Tumors
SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence
This study focuses on rare brain tumors, which are heterogeneous entities with different morphological, biological, and clinical characteristics.
- Trial name
- SIMPLIF-AI (NCT06878469)
- Testing
- RehaCom
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Retina, Choroid, Sclera
Swept Source Enhanced Depth Imaging Optical Coherence Tomography
The investigators would be interested in applying the enhanced depth imaging technique to swept source optical coherence tomography, by modifying the acquisition protocol.
- Trial name
- NCT02443129
- Testing
- DRI-1 Swept source OCT, Atlantis, Topcon
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
Chorioretinitis
To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis
Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The goal of treatment is arresting multiplication of the parasite in its inflammatory active phase.
- Trial name
- NCT00372294
- Testing
- pyrimethamine-sulfadiazine + prednisolone, Clindamycin+Dexamethasone
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Retinal Degeneration, Inherited Retinal Dystrophy Primarily Involving Sensory Retina
Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS
This study aims to assess the impact of the subretinal implant RETINA IMPLANT Alpha AMS on the patient's daily life, using validated activities of daily living and questionnaires.
- Trial name
- NCT03561922
- Testing
- RETINA IMPLANT Alpha AMS
- Where
- 2 sites in France
- Volunteers
- 2 people
- Sponsor
- Retina Implant AG
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming…
- Trial name
- NCT00032045
- Testing
- gp100 antigen, incomplete Freund's adjuvant, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Choroideremia, CHM (Choroideremia) Gene Mutations
Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.
- Trial name
- NCT02341807
- Testing
- AAV2-hCHM
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Spark Therapeutics, Inc.
Retinitis Pigmentosa, Choroideremia
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease
- Trial name
- NCT06375239
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Ray Therapeutics, Inc.
Choroidal Neovascularisation
Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen
This study is designed to provide efficacy and safety data in patients with choroidal neovascularisation (CNV) secondary to myopia using an individualized as-needed (PRN) dosing schedule.
- Trial name
- REPAIR (NCT01037348)
- Testing
- ranibizumab 0.5mg
- Where
- 12 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Novartis
Intraocular Melanoma
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01217398
- Testing
- bevacizumab, temozolomide, polymorphism analysis
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Institut Curie
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
ABT-751 in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00036959
- Testing
- ABT-751
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD)
A Study Of Early Markers Of Choroidal Neovascularization
Identify early markers of choroidal neovascularization (CNV) in the fellow eye of a patient with CNV in the other eye due to age-related macular degeneration with the expectation of being able to identify patients in need of…
- Conditions
- Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers
- Trial name
- NCT00902785
- Testing
- no drug
- Where
- 3 sites in Italy, Portugal and 1 more
- Volunteers
- 100 people
- Sponsor
- Pfizer